Researchers found that a short course of immunotherapy before surgery can keep certain colorectal cancer patients cancer-free for nearly three years. In a UK-led clinical trial, patients with stage two or three colorectal cancer who received nine weeks of pembrolizumab prior to surgery showed remarkable results, with 59% having no detectable cancer after treatment. After 33 months of follow-up, none of the patients experienced a relapse, contrasting sharply with the 25% recurrence rate seen in standard treatments involving surgery followed by chemotherapy.

This finding is significant for anyone concerned about colorectal cancer, especially as the disease is increasingly diagnosed in younger adults. For those diagnosed with stage two or three colorectal cancer, this new approach could mean a much lower chance of cancer returning. The study indicates that starting treatment with immunotherapy may provide longer-lasting protection and better outcomes compared to traditional methods.

The evidence comes from a small clinical trial involving 32 patients with a specific genetic subtype of colorectal cancer. While the results are promising, they are still early-stage and need further validation through larger studies. Researchers are also developing personalized blood tests to predict which patients are most likely to benefit from this treatment, which could lead to more tailored and effective care.

If you or someone you know is facing a colorectal cancer diagnosis, it may be worth discussing the latest treatment options with a healthcare provider, including the potential for immunotherapy as a pre-surgery option, especially if the cancer falls into the specific subtype studied.

Source: sciencedaily.com